Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings

Current Opinion in HIV and AIDS

Volumn 5, Issue 1, 2010, Pages 1-5

  Lynen, Lutgarde ^a   Van Griensven, Johan ^a   Elliott, Julian ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b ALFRED HOSPITAL   (Australia)

Author keywords

Antiretroviral treatment; Monitoring; Resource poor settings; Treatment failure; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ANTIGEN; VIRUS RNA;

ANTIGEN DETECTION; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LOWEST INCOME GROUP; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THERAPY DELAY; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; WORLD HEALTH ORGANIZATION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MONITORING, IMMUNOLOGIC; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 74349095614     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283333762     Document Type: Review

References (51)

1. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 2006; 20:1163-1169.
2. Ferradini L, Laureillard D, Prak N, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 2007; 21:2293-2301.
3. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health 2009; 14:1048-1058.
4. Leger P, Charles M, Severe P, et al. Five-year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009; 361:828-829.
5. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS 2008; 22:2303-2311.
6. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
7. Keiser O, Orrell C, Egger M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008; 5:e148.
8. Renaud-Thery F, Nguimfack BD, Vitoria M, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS 2007; 21 (Suppl 4):S89-S95.
9. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, June 2008. http://www.who.int/hiv/pub/towards-universal-access-report-2008.pdf. [Accessed on 24 July 2008]
10. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22:1305-1312.
11. Fiscus SA, Cheng B, Crowe SM, et al. HIV-1 viral load assays for resourcelimited settings. PLoS Med 2006; 3:e417.
12. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resourcelimited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870-879.
13. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. http:// www.who.int/hiv/pub/guidelines/adult/en/index.html. [Accessed 24 July 2009]
14. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
15. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14:856-861.
16. Meya D, Spacek LA, Tibenderana H, et al. Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. J Int AIDS Soc 2009; 12:3.
17. Moore DM, Mermin J, Awor A, et al. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006; 43:436-439.
18. Chaiwarith R, Wachirakaphan C, Kotarathititum W, et al. Sensitivity and specificity of using CD4p measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand. Int J Infect Dis 2007; 11:413-416.
19. Reynolds SJ, Nakigozi G, Newell K, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS 2009; 23:697-700.
20. Mee P, Fielding KL, Charalambous S, et al. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
21. Lynen L, An S, Koole O, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009; 52:40-48.
22. Moore DM, Awor A, Downing R, et al. CD4p T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477-484.
23. Castelnuovo B, Byakwaga H, Menten J, et al. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome? AIDS 2008; 22:269-273.
24. Bisson GP, Gross R, Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008; 5:e109.
25. Gross R, Bilker WB, Wang H, Chapman J. How long is the window of opportunity between adherence failure and virologic failure on efavirenzbased HAART? HIV Clin Trials 2008; 9:202-206.
26. Elliott JH, Lynen L, Calmy A, et al. Rational use of antiretroviral therapy in lowincome and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22:2053-2067.
27. Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis 2008; 197 (Suppl 3):S272-S278.
28. Calmy A, Pizzocolo C, Pizarro L, et al. The marriage of science and optimized HIV care in resource-limited settings. AIDS 2008; 22:2227-2230.
29. Van Griensven J, Corthouts A, Atté EF, Alonso J. Validity of WHO-recommended immunological criteria for treatment failure [1039]. Presented at 2007 HIV/AIDS Implementers' Meeting; 16-19 June 2007; Kigali, Rwanda.
30. Bisson GP, Gross R, Strom JB, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS 2006; 20:1613-1619.
31. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
32. Colby DJ. Cost-effectiveness of viral load testing for suspected first-line antiretroviral drug therapy failure in Vietnam [1624]. Presented at 2009 HIV/ AIDS Implementer's meeting; 10-14 June 2009; Windhoek, Namibia.
33. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-1134.
34. Kumarasamy N, Madhavan V, Venkatesh KK, et al. High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis 2009; 49:306-309.
35. Seyler C, Adje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21:1157-1164.
36. Phan V, Zolfo M, Koole O, et al. Impact of prolonged detectable HIV RNA after HAART failure in a CRF01-AE infected cohort: pathway and accumulation of resistance mutations [27]. Presented at VII European HIV Drug Resistance Workshop; 25-27 March 2009; Stockholm, Sweden.
37. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-417.
38. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-1322.
39. Hosseinipour M, Kumwenda J, Weigel R, et al. Clinical, immunological, and virological outcomes of second-line treatment, Malawi [605]. Presented at 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
40. Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910-1918.
41. Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451.
42. Mugavero MJ, May M, Harris R, et al. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice? AIDS 2008; 22:2481-2492.
43. Coutinho A, Mermin J, Ekwaru J, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. Presented at 15th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts; 3 February 2008; Abstract no 125.
44. Mugyenyi P, Walker S, Hakim J, et al. Impact of routine laboratory monitoring over 5 years after antiretroviral therapy initiation on clinical disease progression of HIV-infected African adults: the DART Trial final results [103]. Presented at 5th IAS Conference on HIV Pathogenesis and Treatment; 19-22 July 2009; Cape Town, South Africa.
45. Medina LA, Kigozi J, Amurwon J, et al. Cost-effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART Trial) [104]. Presented at 5th IAS Conference on HIV Pathogenesis and Treatment; 19-22 July 2009; Cape Town, South Africa.
46. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
47. Keiser O, ART-LINC Collaboration of IeDEA. Switching to second-line ART, and mortality in resource-limited settings: Collaborative Analysis of Treatment Programs in Africa, Asia, and Latin America [608]. Presented at 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
48. Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-134.
49. Reekie J, Mocroft A, Sambatakou H, et al. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS 2008; 22:2381-2390.
50. Rouet F, Rouzioux C. The measurement of HIV-1 viral load in resource-limited settings: how and where? Clin Lab 2007; 53:135-148.
51. Iqbal HS, Balakrishnan P, Cecelia AJ, et al. Use of an HIV-1 reversetranscriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. J Med Microbiol 2007; 56:1611-1614.